Trial Profile
An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Abacavir; Abacavir/dolutegravir/lamivudine; Atazanavir; Darunavir; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Lamivudine/abacavir; Lopinavir/ritonavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DOLAM
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 16 Feb 2022 Results assessing multiomics plasma profile, presented at the 29th Conference on Retroviruses and Opportunistic Infections.
- 13 Oct 2020 Results (n=15) published in the Journal of Infectious Diseases